The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 794542000640SEQLIST.TXT, date recorded: Mar. 16, 2020, size: 316 KB).
The present disclosure relates to genetically altered plants. In particular, the present disclosure relates to genetically altered plants with enhanced biomass including genetic alterations that stimulate RuBP regeneration including through overexpression of Calvin Benson cycle (CB) proteins such as FBPase/SBPase or SBPase, and including genetic alterations that stimulate electron transport, including through overexpression of photosynthetic electron transport proteins such as cytochrome c6 and Rieske FeS.
The yield potential of crop species is limited by multiple external factors, including agricultural management and environmental conditions. Even under optimal management and conditions, however, the energy conversion efficiency of crop species can still limit yield. Energy conversion efficiency is the ratio of biomass energy produced divided by light energy intercepted by the crop canopy over a given period, and is determined by plant internal processes such as photosynthesis and respiration. Modeling has shown that the energy conversion efficiency of major crop species lags behind other yield potential improvement components, and represents a major roadblock in improving the yield potential of crop species (Zhu, et al., Annu. Rev. Plant. Biol. (2010) 61:235-261).
The Calvin Benson cycle (CB) is a promising target for improving photosynthesis, as it is involved in assimilating carbon, i.e., producing biomass energy. Early studies showed that even small reductions in individual CB enzymes are sufficient to reduce carbon assimilation and plant growth. While some enzymes have a larger effect than others, research has shown that overexpressing different individual CB enzymes results in increased photosynthetic carbon assimilation and improved plant growth. Therefore, there is no single limiting step in photosynthetic carbon assimilation. This means that although manipulating CB enzyme activity might be used to increase productivity, developing an effective engineering strategy for major crop species has proven to date to not be as simple as altering one component.
Photosynthetic electron transport is another possible target for improving photosynthesis, as it is involved in harnessing the light energy intercepted by the crop canopy. Individual components of the photosynthetic electron transport chain have been shown to be able to increase electron transport rates. For example, overexpression of the plant Rieske FeS protein resulted in increased electron transport rates and increased plant biomass (Simkin, et al., Plant Physiol. (2017) 175:134-145). While individual components have provided promising results, studies have shown that overall, the efficiency of photosynthetic electron transport in higher plants is limited by the photosynthetic electron transport proteins of higher plants, such as plastocyanin (Chida, et al., Plant Cell Physiol. (2007) 48:948-957; Finazzi, et al., Proc. Natl. Acad. Sci. USA. (2005) 102:7031-7036).
There exists a clear need for improved energy conversion efficiency in order to achieve optimal yield potential of crop species. In order to develop plants with improved energy conversion efficiency, multi-component engineering incorporating different aspects of photosynthesis is required.
In order to meet these needs, the present disclosure provides means of enhancing plant biomass by stimulating RuBP regeneration and electron transport. In particular, the present disclosure relates to genetically altered plants with enhanced biomass through overexpression of CB proteins (e.g., FBPase/SBPase or SBPase), and overexpression of photosynthetic electron transport proteins (e.g., cytochrome c6 and Rieske FeS).
An aspect of the disclosure includes a genetically altered plant, plant part, or plant cell, wherein the plant, part thereof or cell includes one or more RuBP regeneration enhancing genetic alterations that increase activity of a CB protein and one or more photosynthetic electron transport enhancing genetic alterations. An additional embodiment of this aspect includes the one or more photosynthetic electron transport enhancing genetic alterations being overexpression of one or more photosynthetic electron transport proteins. Yet another embodiment of this aspect includes the one or more photosynthetic electron transport proteins being selected from the group of a cytochrome c6 protein, a Rieske FeS protein, or a cytochrome c6 protein and a Rieske FeS protein. A further embodiment of this aspect includes the one or more photosynthetic electron transport proteins being a cytochrome c6 protein. Still another embodiment of this aspect includes the cytochrome c6 protein being an algal cytochrome c6 protein. In an additional embodiment of this aspect, the algal cytochrome c6 protein includes an amino acid sequence with at least 70% sequence identity to, at least 75% sequence identity to, at least 80% sequence identity to, at least 85% sequence identity to, at least 90% sequence identity to, at least 95% sequence identity to, or at least 99% sequence identity to SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 95, or SEQ ID NO: 102. In a further embodiment of this aspect, the algal cytochrome c6 protein includes an amino acid sequence with at least 70% sequence identity to, at least 75% sequence identity to, at least 80% sequence identity to, at least 85% sequence identity to, at least 90% sequence identity to, at least 95% sequence identity to, or at least 99% sequence identity to SEQ ID NO: 95. An additional embodiment of this aspect includes the one or more photosynthetic electron transport proteins being a Rieske FeS protein. In a further embodiment of this aspect, the Rieske FeS protein includes an amino acid sequence with at least 70% sequence identity to, at least 75% sequence identity to, at least 80% sequence identity to, at least 85% sequence identity to, at least 90% sequence identity to, at least 95% sequence identity to, or at least 99% sequence identity to SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, or SEQ ID NO: 101. An additional embodiment of this aspect includes the one or more photosynthetic electron transport proteins being a cytochrome c6 protein and a Rieske FeS protein. In a further embodiment of this aspect, the cytochrome c6 protein includes an amino acid sequence with at least 70% sequence identity to, at least 75% sequence identity to, at least 80% sequence identity to, at least 85% sequence identity to, at least 90% sequence identity to, at least 95% sequence identity to, or at least 99% sequence identity to SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 95, or SEQ ID NO: 102; and the Rieske FeS protein includes an amino acid sequence with at least 70% sequence identity to, at least 75% sequence identity to, at least 80% sequence identity to, at least 85% sequence identity to, at least 90% sequence identity to, at least 95% sequence identity to, or at least 99% sequence identity to SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, or SEQ ID NO: 101.
In yet another embodiment of this present aspect, which may be combined with any of the preceding embodiments that has cytochrome c6, the cytochrome c6 protein is localized to a thylakoid lumen of at least one chloroplast within a cell of the genetically altered plant. A further embodiment of this aspect includes the cytochrome c6 protein including a transit peptide that localizes the cytochrome c6 protein to the thylakoid lumen. An additional embodiment of this aspect includes the cytochrome c6 transit peptide being selected from the group of a chlorophyll a/b binding protein 6 transit peptide, a light-harvesting complex I chlorophyll a/b binding protein 1 transit peptide, or a plastocyanin signal peptide. In still another embodiment of this present aspect, which may be combined with any of the preceding embodiments that has Rieske FeS, the Rieske FeS protein includes a transit peptide that localizes the Rieske FeS protein to the thylakoid membrane. An additional embodiment of this aspect includes the Rieske FeS transit peptide being selected from the group of a cytochrome f transit peptide, a cytochrome b6 transit peptide, a PetD transit peptide, a PetG transit peptide, a PetL transit peptide, a PetN transit peptide, a PetM transit peptide, and a plastoquinone transit peptide. Still another embodiment of this aspect that can be combined with any of the preceding embodiments that has cytochrome c6 further includes a cytochrome c6 protein encoding nucleic acid sequence operably linked to a plant promoter. A further embodiment of this aspect includes the promoter being selected from a constitutive promoter, an inducible promoter, a tissue or cell type specific promoter, or an inducible, tissue or cell type specific promoter. Yet another embodiment of this aspect that can be combined with any of the preceding embodiments that has Rieske FeS further includes a Rieske FeS protein encoding nucleic acid sequence operably linked to a plant promoter. An additional embodiment of this aspect includes the promoter being selected from a constitutive promoter, an inducible promoter, a tissue or cell type specific promoter, or an inducible, tissue or cell type specific promoter.
In still another embodiment of this aspect that can be combined with any of the preceding embodiments, the one or more RuBP regeneration enhancing genetic alterations include overexpression of a CB protein. An additional embodiment of this aspect includes the CB protein being selected from the group of a sedoheptulose-1,7-bisphosphatase (SBPase), a fructose-1,6-bisphophate aldolase (FBPA), a chloroplastic fructose-1,6-bisphosphatase (FBPase), a bifunctional fructose-1,6-bisphosphatases/sedoheptulose-1,7-bisphosphatase (FBP/SBPase), or a transketolase (TK). A further embodiment of this aspect includes the CB protein being a SBPase. In yet another embodiment of this aspect, the SBPase includes an amino acid sequence with at least 70% sequence identity to, at least 75% sequence identity to, at least 80% sequence identity to, at least 85% sequence identity to, at least 90% sequence identity to, at least 95% sequence identity to, or at least 99% sequence identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 96. A further embodiment of this aspect includes the SBPase being localized to a chloroplast stroma of at least one chloroplast within a cell of the genetically altered plant. In yet another embodiment of this aspect, the SBPase includes a transit peptide that localizes the SBPase to the chloroplast stroma. Still another embodiment of this aspect that can be combined with any of the preceding embodiments that has SBPase further includes a SBPase encoding nucleic acid sequence operably linked to a plant promoter. An additional embodiment of this aspect includes the promoter being selected from a constitutive promoter, an inducible promoter, a tissue or cell type specific promoter, or an inducible, tissue or cell type specific promoter. A further embodiment of this aspect includes the CB protein being a FBPA. In yet another embodiment of this aspect, the FBPA includes an amino acid sequence with at least 70% sequence identity to, at least 75% sequence identity to, at least 80% sequence identity to, at least 85% sequence identity to, at least 90% sequence identity to, at least 95% sequence identity to, or at least 99% sequence identity to SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, or SEQ ID NO: 97. A further embodiment of this aspect includes the FBPA being localized to a chloroplast stroma of at least one chloroplast within a cell of the genetically altered plant. In yet another embodiment of this aspect, the FBPA includes a transit peptide that localizes the FBPA to the chloroplast stroma. Still another embodiment of this aspect that can be combined with any of the preceding embodiments that has FBPA further includes a FBPA encoding nucleic acid sequence operably linked to a plant promoter. An additional embodiment of this aspect includes the promoter being selected from a constitutive promoter, an inducible promoter, a tissue or cell type specific promoter, or an inducible, tissue or cell type specific promoter. A further embodiment of this aspect includes the CB protein being a FBPase. In yet another embodiment of this aspect, the FBPase includes an amino acid sequence with at least 70% sequence identity to, at least 75% sequence identity to, at least 80% sequence identity to, at least 85% sequence identity to, at least 90% sequence identity to, at least 95% sequence identity to, or at least 99% sequence identity to SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, or SEQ ID NO: 98. A further embodiment of this aspect includes the FBPase being localized to a chloroplast stroma of at least one chloroplast within a cell of the genetically altered plant. In yet another embodiment of this aspect, the FBPase includes a transit peptide that localizes the FBPase to the chloroplast stroma. Still another embodiment of this aspect that can be combined with any of the preceding embodiments that has FBPase further includes a FBPase encoding nucleic acid sequence operably linked to a plant promoter. An additional embodiment of this aspect includes the promoter being selected from a constitutive promoter, an inducible promoter, a tissue or cell type specific promoter, or an inducible, tissue or cell type specific promoter. A further embodiment of this aspect includes the CB protein being a FBP/SBPase. An additional embodiment of this aspect includes the FBP/SBPase being a cyanobacterial FBP/SBPase. In yet another embodiment of this aspect, the cyanobacterial FBP/SBPase includes an amino acid sequence with at least 70% sequence identity to, at least 75% sequence identity to, at least 80% sequence identity to, at least 85% sequence identity to, at least 90% sequence identity to, at least 95% sequence identity to, or at least 99% sequence identity to SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, or SEQ ID NO: 99. Still another embodiment of this aspect that can be combined with any of the preceding embodiments that has FBP/SBPase includes the FBP/SBPase being localized to a chloroplast stroma of at least one chloroplast within a cell of the genetically altered plant. In a further embodiment of this aspect, the FBP/SBPase includes a transit peptide that localizes the FBP/SBPase to the chloroplast stroma. An additional embodiment of this aspect include the transit peptide being selected from the group of a geraniol synthase transit peptide, a SBPase transit peptide, a FBPA transit peptide, a FBPase transit peptide, a transketolase transit peptide, a PGK transit peptide, a GAPDH transit peptide, an AGPase transit peptide, a RPI transit peptide, a RPE transit peptide, a PRK transit peptide, or a Rubisco transit peptide. Yet another embodiment of this aspect that can be combined with any of the preceding embodiments that has FBP/SBPase further includes a FBP/SBPase encoding nucleic acid sequence operably linked to a plant promoter. S An additional embodiment of this aspect includes the promoter being selected from a constitutive promoter, an inducible promoter, a tissue or cell type specific promoter, or an inducible, tissue or cell type specific promoter. A further embodiment of this aspect includes the CB protein being a transketolase. In yet another embodiment of this aspect, the transketolase includes an amino acid sequence with at least 70% sequence identity to, at least 75% sequence identity to, at least 80% sequence identity to, at least 85% sequence identity to, at least 90% sequence identity to, at least 95% sequence identity to, or at least 99% sequence identity to SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 100. A further embodiment of this aspect includes the transketolase being localized to a chloroplast stroma of at least one chloroplast within a cell of the genetically altered plant. Yet another embodiment of this aspect that can be combined with any of the preceding embodiments that has transketolase further includes a transketolase encoding nucleic acid sequence operably linked to a plant promoter. An additional embodiment of this aspect includes the promoter being selected from a constitutive promoter, an inducible promoter, a tissue or cell type specific promoter, or an inducible, tissue or cell type specific promoter.
A further embodiment of this aspect that can be combined with any of the preceding embodiments that has a CB protein which could be endogenous to the plant includes the nucleic acid encoding the CB protein being endogenous. An additional embodiment of this aspect includes the promoter operably linked to the nucleic acid encoding the CB protein being genetically engineered to overexpress, inducibly express, express in a specific tissue or cell type, inducibly overexpress, or inducibly express in a specific tissue or cell type the CB protein. Still another embodiment of this aspect that can be combined with any of the preceding embodiments that has a CB protein includes the nucleic acid encoding the CB protein being heterologous.
Still another embodiment of this aspect that can be combined with any of the preceding embodiments that has a Rieske FeS protein encoding nucleic acid sequence includes the nucleic acid encoding the Rieske FeS protein being endogenous. An additional embodiment of this aspect includes the promoter operably linked to the nucleic acid encoding the Rieske FeS protein being genetically engineered to overexpress, inducibly express, express in a specific tissue or cell type, inducibly overexpress, or inducibly express in a specific tissue or cell type the Rieske FeS protein. Still another embodiment of this aspect that can be combined with any of the preceding embodiments that has a Rieske FeS protein encoding nucleic acid sequence includes the nucleic acid encoding the CB protein being heterologous.
In yet another embodiment of this aspect, which may be combined with any of the preceding embodiments, the plant has increased biomass as compared to an unaltered wild type (WT) plant. An additional embodiment of this aspect includes the plant having improved water use efficiency as compared to an unaltered WT plant when grown in conditions with light intensities above 1000 μmol m2 s−1. A further embodiment of this aspect includes the plant being selected from the group of cowpea, soybean, cassava, rice, wheat, barley, tomato, potato, tobacco, canola, or other C3 crop plants. Still another embodiment of this aspect includes the plant being selected from the group of cowpea, soybean, cassava, rice, wheat, barley, and tobacco.
Yet another embodiment of this aspect that can be combined with any of the preceding embodiments with respect to plant part includes the plant part being a leaf, a stem, a root, a tuber, a flower, a seed, a kernel, a grain, a fruit, a cell, or a portion thereof and the genetically altered plant part including the one or more genetic alterations. A further embodiment of this aspect includes the plant part being a fruit, a tuber, a kernel, or a grain. Still another embodiment of this aspect that can be combined with any of the preceding embodiments with respect to pollen grain or ovules includes a genetically altered pollen grain or a genetically altered ovule of the plant of any one of the preceding embodiments, wherein the genetically altered pollen grain or the genetically altered ovule includes the one or more genetic alterations. A further embodiment of this aspect that can be combined with any of the preceding embodiments includes a genetically altered protoplast produced from the genetically altered plant of any of the preceding embodiments, wherein the genetically altered protoplast includes the one or more genetic alterations. An additional embodiment of this aspect that can be combined with any of the preceding embodiments includes a genetically altered tissue culture produced from protoplasts or cells from the genetically altered plant of any one of the preceding embodiments, wherein the cells or protoplasts are produced from a plant part selected from the group of leaf, leaf mesophyll cell, anther, pistil, stem, petiole, root, root tip, tuber, fruit, seed, kernel, grain, flower, cotyledon, hypocotyl, embryo, or meristematic cell, wherein the genetically altered tissue culture includes the one or more genetic alterations. An additional embodiment of this aspect includes a genetically altered plant regenerated from the genetically altered tissue culture that includes the one or more genetic alterations. Yet another embodiment of this aspect that can be combined with any of the preceding embodiments includes a genetically altered plant seed produced from the genetically altered plant of any one of the preceding embodiments.
An additional aspect of the disclosure includes methods of producing the genetically altered plant of any of the preceding embodiments including (a) introducing the one or more RuBP regeneration enhancing genetic alterations that increase activity of a CB protein, the one or more photosynthetic electron transport enhancing genetic alterations, or both the one or more RuBP regeneration enhancing genetic alterations that increase activity of a CB protein and the one or more photosynthetic electron transport enhancing genetic alterations into a plant cell, tissue, or other explant; (b) regenerating the plant cell, tissue, or other explant into a genetically altered plantlet; and (c) growing the genetically altered plantlet into a genetically altered plant with the one or more RuBP regeneration enhancing genetic alterations that increase activity of a CB protein, the one or more photosynthetic electron transport enhancing genetic alterations, or both the one or more RuBP regeneration enhancing genetic alterations that increase activity of a CB protein and the one or more photosynthetic electron transport enhancing genetic alterations. An additional embodiment of this aspect further includes identifying successful introduction of the one or more genetic alterations by screening or selecting the plant cell, tissue, or other explant prior to step (b); screening or selecting plantlets between step (b) and (c); or screening or selecting plants after step (c). In yet another embodiment of this aspect, which may be combined with any of the preceding embodiments, transformation is done using a transformation method selected from the group of particle bombardment (i.e., biolistics, gene gun), Agrobacterium-mediated transformation, Rhizobium-mediated transformation, or protoplast transfection or transformation.
Still another embodiment of this aspect that can be combined with any of the preceding embodiments includes genetic alterations being introduced with a vector. In an additional embodiment of this aspect, the vector includes a promoter operably linked to a nucleotide encoding one or more photosynthetic electron transport proteins, a nucleotide encoding one or more CB proteins, or a nucleotide encoding one or more photosynthetic electron transport protein and one or more CB proteins. Yet another embodiment of this aspect includes the promoter being selected from the group of a constitutive promoter, an inducible promoter, a tissue or cell type specific promoter, or an inducible, tissue or cell type specific promoter. In a further embodiment of this aspect, which may be combined with any of the preceding embodiments, the photosynthetic electron transport protein is selected from the group of a cytochrome c6 protein, a Rieske FeS protein, or a cytochrome c6 protein and a Rieske FeS protein. In yet another embodiment of this aspect, the cytochrome c6 protein includes an amino acid sequence with at least 70% sequence identity to, at least 75% sequence identity to, at least 80% sequence identity to, at least 85% sequence identity to, at least 90% sequence identity to, at least 95% sequence identity to, or at least 99% sequence identity to SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 95, or SEQ ID NO: 102. In still another embodiment of this aspect, the Rieske FeS protein includes an amino acid sequence with at least 70% sequence identity to, at least 75% sequence identity to, at least 80% sequence identity to, at least 85% sequence identity to, at least 90% sequence identity to, at least 95% sequence identity to, or at least 99% sequence identity to SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, or SEQ ID NO: 101. In a further embodiment of this aspect, the vector includes one or more gene editing components that target a nuclear genome sequence operably linked to the nucleic acid encoding the CB protein. In yet another embodiment of this present aspect, the one or more gene editing components are selected from the group of a ribonucleoprotein complex that targets the nuclear genome sequence; a vector including a TALEN protein encoding sequence, wherein the TALEN protein targets the nuclear genome sequence; a vector including a ZFN protein encoding sequence, wherein the ZFN protein targets the nuclear genome sequence; an oligonucleotide donor (ODN), wherein the ODN targets the nuclear genome sequence; or a vector including a CRISPR/Cas enzyme encoding sequence and a targeting sequence, wherein the targeting sequence targets the nuclear genome sequence.
In a further embodiment of this aspect that can be combined with any of the preceding embodiments that has a vector including a nucleotide encoding one or more CB proteins, the CB protein is selected from the group of a sedoheptulose-1,7-bisphosphatase (SBPase), a fructose-1,6-bisphophate aldolase (FBPA), a chloroplastic fructose-1,6-bisphosphatase (FBPase), a bifunctional fructose-1,6-bisphosphatases/sedoheptulose-1,7-bisphosphatase (FBP/SBPase), or a transketolase (TK). In an additional embodiment of this aspect, the CB protein is a SBPase, and the SBPase includes an amino acid sequence with at least 70% sequence identity to, at least 75% sequence identity to, at least 80% sequence identity to, at least 85% sequence identity to, at least 90% sequence identity to, at least 95% sequence identity to, or at least 99% sequence identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 96. In another embodiment of this aspect, the CB protein is a FBPA, and the FBPA includes an amino acid sequence with at least 70% sequence identity to, at least 75% sequence identity to, at least 80% sequence identity to, at least 85% sequence identity to, at least 90% sequence identity to, at least 95% sequence identity to, or at least 99% sequence identity to SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, or SEQ ID NO: 97. In still another embodiment of this aspect, the CB protein is a FBPase, and the FBPase includes an amino acid sequence with at least 70% sequence identity to, at least 75% sequence identity to, at least 80% sequence identity to, at least 85% sequence identity to, at least 90% sequence identity to, at least 95% sequence identity to, or at least 99% sequence identity to SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, or SEQ ID NO: 98. In a further embodiment of this aspect, the CB protein is a FBP/SBPase, and the FBP/SBPase includes an amino acid sequence with at least 70% sequence identity to, at least 75% sequence identity to, at least 80% sequence identity to, at least 85% sequence identity to, at least 90% sequence identity to, at least 95% sequence identity to, or at least 99% sequence identity to SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, or SEQ ID NO: 99. In yet another embodiment of this aspect, the CB protein is a transketolase, and the transketolase includes an amino acid sequence with at least 70% sequence identity to, at least 75% sequence identity to, at least 80% sequence identity to, at least 85% sequence identity to, at least 90% sequence identity to, at least 95% sequence identity to, or at least 99% sequence identity to SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 100.
A further aspect of the disclosure includes methods of cultivating the genetically altered plant of any of the preceding embodiments that has a genetically altered plant, including the steps of: planting a genetically altered seedling, a genetically altered plantlet, a genetically altered cutting, a genetically altered tuber, a genetically altered root, or a genetically altered seed in soil to produce the genetically altered plant or grafting the genetically altered seedling, the genetically altered plantlet, or the genetically altered cutting to a root stock or a second plant grown in soil to produce the genetically altered plant; cultivating the plant to produce harvestable seed, harvestable leaves, harvestable roots, harvestable cuttings, harvestable wood, harvestable fruit, harvestable kernels, harvestable tubers, and/or harvestable grain; and harvesting the harvestable seed, harvestable leaves, harvestable roots, harvestable cuttings, harvestable wood, harvestable fruit, harvestable kernels, harvestable tubers, and/or harvestable grain.
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
The following description sets forth exemplary methods, parameters, and the like. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments.
An aspect of the disclosure includes a genetically altered plant, plant part, or plant cell, wherein the plant, part thereof or cell includes one or more RuBP regeneration enhancing genetic alterations that increase activity of a CB protein and one or more photosynthetic electron transport enhancing genetic alterations. An additional embodiment of this aspect includes the one or more photosynthetic electron transport enhancing genetic alterations being overexpression of one or more photosynthetic electron transport proteins. Yet another embodiment of this aspect includes the one or more photosynthetic electron transport proteins being selected from the group of a cytochrome c6 protein, a Rieske FeS protein, or a cytochrome c6 protein and a Rieske FeS protein. A further embodiment of this aspect includes the one or more photosynthetic electron transport proteins being a cytochrome c6 protein. Still another embodiment of this aspect includes the cytochrome c6 protein being an algal cytochrome c6 protein. In an additional embodiment of this aspect, the algal cytochrome c6 protein includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 95, or SEQ ID NO: 102. In a further embodiment of this aspect, the algal cytochrome c6 protein includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: 95. In yet another embodiment of this aspect, the algal cytochrome c6 protein includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: 102. An additional embodiment of this aspect includes the one or more photosynthetic electron transport proteins being a Rieske FeS protein. In a further embodiment of this aspect, the Rieske FeS protein includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, or SEQ ID NO: 101. In still another embodiment of this aspect, the Rieske FeS protein includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: 101. An additional embodiment of this aspect includes the one or more photosynthetic electron transport proteins being a cytochrome c6 protein and a Rieske FeS protein. In a further embodiment of this aspect, the cytochrome c6 protein includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 95, or SEQ IF NO: 102; and the Rieske FeS protein includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, or SEQ ID NO: 101.
In yet another embodiment of this present aspect, which may be combined with any of the preceding embodiments that has cytochrome c6, the cytochrome c6 protein is localized to a thylakoid lumen of at least one chloroplast within a cell of the genetically altered plant. A further embodiment of this aspect includes the cytochrome c6 protein including a transit peptide that localizes the cytochrome c6 protein to the thylakoid lumen. An additional embodiment of this aspect includes the cytochrome c6 transit peptide being selected from the group of a chlorophyll a/b binding protein 6 transit peptide, a light-harvesting complex I chlorophyll a/b binding protein 1 transit peptide, or a plastocyanin signal peptide. In still another embodiment of this present aspect, which may be combined with any of the preceding embodiments that has Rieske FeS, the Rieske FeS protein includes a transit peptide that localizes the Rieske FeS protein to the thylakoid membrane. Another embodiment of this present aspect includes the Rieske FeS transit peptide being a cytochrome b6f complex protein transit peptide. An additional embodiment of this aspect includes the Rieske FeS transit peptide being selected from the group of a cytochrome f transit peptide, a cytochrome b6 transit peptide, a PetD transit peptide, a PetG transit peptide, a PetL transit peptide, a PetN transit peptide, a PetM transit peptide, and a plastoquinone transit peptide. Still another embodiment of this aspect that can be combined with any of the preceding embodiments that has cytochrome c6 further includes a cytochrome c6 protein encoding nucleic acid sequence operably linked to a plant promoter. A further embodiment of this aspect includes the promoter being selected from a constitutive promoter, an inducible promoter, a tissue or cell type specific promoter, or an inducible, tissue or cell type specific promoter. Yet another embodiment of this aspect that can be combined with any of the preceding embodiments that has Rieske FeS further includes a Rieske FeS protein encoding nucleic acid sequence operably linked to a plant promoter. An additional embodiment of this aspect includes the promoter being selected from a constitutive promoter, an inducible promoter, a tissue or cell type specific promoter, or an inducible, tissue or cell type specific promoter.
In still another embodiment of this aspect that can be combined with any of the preceding embodiments, the one or more RuBP regeneration enhancing genetic alterations include overexpression of a CB protein. An additional embodiment of this aspect includes the CB protein being selected from the group of a sedoheptulose-1,7-bisphosphatase (SBPase), a fructose-1,6-bisphophate aldolase (FBPA), a chloroplastic fructose-1,6-bisphosphatase (FBPase), a bifunctional fructose-1,6-bisphosphatases/sedoheptulose-1,7-bisphosphatase (FBP/SBPase), or a transketolase (TK). A further embodiment of this aspect includes the CB protein being a SBPase. In yet another embodiment of this aspect, the SBPase includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 96. In still another embodiment of this aspect, the SBPase includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: 96. A further embodiment of this aspect includes the SBPase being localized to a chloroplast stroma of at least one chloroplast within a cell of the genetically altered plant. In yet another embodiment of this aspect, the SBPase includes a transit peptide that localizes the SBPase to the chloroplast stroma. Still another embodiment of this aspect that can be combined with any of the preceding embodiments that has SBPase further includes a SBPase encoding nucleic acid sequence operably linked to a plant promoter. An additional embodiment of this aspect includes the promoter being selected from a constitutive promoter, an inducible promoter, a tissue or cell type specific promoter, or an inducible, tissue or cell type specific promoter. A further embodiment of this aspect includes the CB protein being a FBPA. In yet another embodiment of this aspect, the FBPA includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, or SEQ ID NO: 97. In still another embodiment of this aspect, the FBPA includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: 97. A further embodiment of this aspect includes the FBPA being localized to a chloroplast stroma of at least one chloroplast within a cell of the genetically altered plant. In yet another embodiment of this aspect, the EBPA includes a transit peptide that localizes the FBPA to the chloroplast stroma. Still another embodiment of this aspect that can be combined with any of the preceding embodiments that has FBPA further includes a FBPA encoding nucleic acid sequence operably linked to a plant promoter. An additional embodiment of this aspect includes the promoter being selected from a constitutive promoter, an inducible promoter, a tissue or cell type specific promoter, or an inducible, tissue or cell type specific promoter. A further embodiment of this aspect includes the CB protein being a FBPase. In yet another embodiment of this aspect, the FBPase includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, or SEQ ID NO: 98. In still another embodiment of this aspect, the FBPase includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: 98. A further embodiment of this aspect includes the FBPase being localized to a chloroplast stroma of at least one chloroplast within a cell of the genetically altered plant. In yet another embodiment of this aspect, the FBPase includes a transit peptide that localizes the FBPase to the chloroplast stroma. Still another embodiment of this aspect that can be combined with any of the preceding embodiments that has FBPase further includes a FBPase encoding nucleic acid sequence operably linked to a plant promoter. An additional embodiment of this aspect includes the promoter being selected from a constitutive promoter, an inducible promoter, a tissue or cell type specific promoter, or an inducible, tissue or cell type specific promoter. A further embodiment of this aspect includes the CB protein being a FBP/SBPase. An additional embodiment of this aspect includes the FBP/SBPase being a cyanobacterial FBP/SBPase. In yet another embodiment of this aspect, the cyanobacterial FBP/SBPase includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, or SEQ ID NO: 99. In still another embodiment of this aspect, the cyanobacterial FBP/SBPase includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: 99. Still another embodiment of this aspect that can be combined with any of the preceding embodiments that has FBP/SBPase includes the FBP/SBPase being localized to a chloroplast stroma of at least one chloroplast within a cell of the genetically altered plant. In a further embodiment of this aspect, the FBP/SBPase includes a transit peptide that localizes the FBP/SBPase to the chloroplast stroma. Yet another embodiment of this aspect includes the transit peptide being a chloroplast stromal protein transit peptide in plant. An additional embodiment of this aspect include the transit peptide being selected from the group of a geraniol synthase transit peptide, a SBPase transit peptide, a FBPA transit peptide, a FBPase transit peptide, a transketolase transit peptide, a PGK transit peptide, a GAPDH transit peptide, an AGPase transit peptide, a RPI transit peptide, a RPE transit peptide, a PRK transit peptide, or a Rubisco transit peptide. Yet another embodiment of this aspect that can be combined with any of the preceding embodiments that has 1-BP/SBPase further includes a FBP/SBPase encoding nucleic acid sequence operably linked to a plant promoter. S An additional embodiment of this aspect includes the promoter being selected from a constitutive promoter, an inducible promoter, a tissue or cell type specific promoter, or an inducible, tissue or cell type specific promoter. A further embodiment of this aspect includes the CB protein being a transketolase. In yet another embodiment of this aspect, the transketolase includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 100. In still another embodiment of this aspect, the transketolase includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: 100. A further embodiment of this aspect includes the transketolase being localized to a chloroplast stroma of at least one chloroplast within a cell of the genetically altered plant. Yet another embodiment of this aspect that can be combined with any of the preceding embodiments that has transketolase further includes a transketolase encoding nucleic acid sequence operably linked to a plant promoter. An additional embodiment of this aspect includes the promoter being selected from a constitutive promoter, an inducible promoter, a tissue or cell type specific promoter, or an inducible, tissue or cell type specific promoter.
A further embodiment of this aspect that can be combined with any of the preceding embodiments that has a CB protein that is not 1-BP/SBPase includes the nucleic acid encoding the CB protein being endogenous. An additional embodiment of this aspect includes the promoter operably linked to the nucleic acid encoding the CB protein being genetically engineered to overexpress, inducibly express, express in a specific tissue or cell type, inducibly overexpress, or inducibly express in a specific tissue or cell type the CB protein. Still another embodiment of this aspect that can be combined with any of the preceding embodiments that has a CB protein includes the nucleic acid encoding the CB protein being heterologous.
In yet another embodiment of this aspect, which may be combined with any of the preceding embodiments, the plant has increased biomass as compared to an unaltered wild type (WT) plant. An additional embodiment of this aspect includes the plant having improved water use efficiency as compared to an unaltered WT plant when grown in conditions with light intensities above 1000 μmol m2 s−1. A further embodiment of this aspect includes the plant being selected from the group of cowpea (e.g., black-eyed pea, catjang, yardlong bean, Vigna unguiculata), soybean (e.g., Glycine max, Glycine soja), cassava (e.g., manioc, yucca, Manihot esculenta), rice (e.g., indica rice, japonica rice, aromatic rice, glutinous rice, Oryza sativa, Oryza glaberrima), wheat (e.g., common wheat, spelt, durum, einkorn, emmer, kamut, Triticum aestivum, Triticum spelta, Triticum durum, Triticum urartu, Triticum monococcum, Triticum turanicum, Triticum spp.), barley (e.g., Hordeum vulgare), tomato (e.g., Solanum lycopersicum), potato (e.g., russet potatoes, yellow potatoes, red potatoes, Solanum tuberosum), tobacco (e.g., Nicotiana tabacum), canola (e.g., Brassica rapa, Brassica napus, Brassica juncea), or other C3 crop plants. Still another embodiment of this aspect includes the plant being selected from the group of cowpea (e.g., black-eyed pea, catjang, yardlong bean, Vigna unguiculata), soybean (e.g., Glycine max, Glycine soja), cassava (e.g., manioc, yucca, Manihot esculenta), rice (e.g., indica rice, japonica rice, aromatic rice, glutinous rice, Oryza sativa, Oryza glaberrima), wheat (e.g., common wheat, spelt, durum, einkorn, emmer, kamut, Triticum aestivum, Triticum spelta, Triticum durum, Triticum urartu, Triticum monococcum, Triticum turanicum, Triticum spp.), barley (e.g., Hordeum vulgare), and tobacco (e.g., Nicotiana tabacum).
Yet another embodiment of this aspect that can be combined with any of the preceding embodiments with respect to plant part includes the plant part being a leaf, a stem, a root, a tuber, a flower, a seed, a kernel, a grain, a fruit, a cell, or a portion thereof and the genetically altered plant part including the one or more genetic alterations. A further embodiment of this aspect includes the plant part being a fruit, a tuber, a kernel, or a grain. Still another embodiment of this aspect that can be combined with any of the preceding embodiments with respect to pollen grain or ovules includes a genetically altered pollen grain or a genetically altered ovule of the plant of any one of the preceding embodiments, wherein the genetically altered pollen grain or the genetically altered ovule includes the one or more genetic alterations. A further embodiment of this aspect that can be combined with any of the preceding embodiments includes a genetically altered protoplast produced from the genetically altered plant of any of the preceding embodiments, wherein the genetically altered protoplast includes the one or more genetic alterations. An additional embodiment of this aspect that can be combined with any of the preceding embodiments includes a genetically altered tissue culture produced from protoplasts or cells from the genetically altered plant of any one of the preceding embodiments, wherein the cells or protoplasts are produced from a plant part selected from the group of leaf, leaf mesophyll cell, anther, pistil, stem, petiole, root, root tip, tuber, fruit, seed, kernel, grain, flower, cotyledon, hypocotyl, embryo, or meristematic cell, wherein the genetically altered tissue culture includes the one or more genetic alterations. An additional embodiment of this aspect includes a genetically altered plant regenerated from the genetically altered tissue culture that includes the one or more genetic alterations. Yet another embodiment of this aspect that can be combined with any of the preceding embodiments includes a genetically altered plant seed produced from the genetically altered plant of any one of the preceding embodiments.
An additional aspect of the disclosure includes methods of producing the genetically altered plant of any of the preceding embodiments including (a) introducing the one or more RuBP regeneration enhancing genetic alterations that increase activity of a CB protein, the one or more photosynthetic electron transport enhancing genetic alterations, or both the one or more RuBP regeneration enhancing genetic alterations that increase activity of a CB protein and the one or more photosynthetic electron transport enhancing genetic alterations into a plant cell, tissue, or other explant; (b) regenerating the plant cell, tissue, or other explant into a genetically altered plantlet; and (c) growing the genetically altered plantlet into a genetically altered plant with the one or more RuBP regeneration enhancing genetic alterations that increase activity of a CB protein, the one or more photosynthetic electron transport enhancing genetic alterations, or both the one or more RuBP regeneration enhancing genetic alterations that increase activity of a CB protein and the one or more photosynthetic electron transport enhancing genetic alterations. An additional embodiment of this aspect further includes identifying successful introduction of the one or more genetic alterations by screening or selecting the plant cell, tissue, or other explant prior to step (b); screening or selecting plantlets between step (b) and (c); or screening or selecting plants after step (c). In yet another embodiment of this aspect, which may be combined with any of the preceding embodiments, transformation is done using a transformation method selected from the group of particle bombardment (i.e., biolistics, gene gun), Agrobacterium-mediated transformation, Rhizobium-mediated transformation, or protoplast transfection or transformation.
Still another embodiment of this aspect that can be combined with any of the preceding embodiments includes genetic alterations being introduced with a vector. In an additional embodiment of this aspect, the vector includes a promoter operably linked to a nucleotide encoding one or more photosynthetic electron transport proteins, a nucleotide encoding one or more CB proteins, or a nucleotide encoding one or more photosynthetic electron transport protein and one or more CB proteins. Yet another embodiment of this aspect includes the promoter being selected from the group of a constitutive promoter, an inducible promoter, a tissue or cell type specific promoter, or an inducible, tissue or cell type specific promoter. In a further embodiment of this aspect, which may be combined with any of the preceding embodiments, the photosynthetic electron transport protein is selected from the group of a cytochrome c6 protein, a Rieske FeS protein, or a cytochrome c6 protein and a Rieske FeS protein. In yet another embodiment of this aspect, the cytochrome c6 protein includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 95, or SEQ ID NO: 102.
In a further embodiment of this aspect that can be combined with any of the preceding embodiments that has a vector including a nucleotide encoding one or more CB proteins, the CB protein is selected from the group of a sedoheptulose-1,7-bisphosphatase (SBPase), a fructose-1,6-bisphophate aldolase (FBPA), a chloroplastic fructose-1,6-bisphosphatase (FBPase), a bifunctional fructose-1,6-bisphosphatases/sedoheptulose-1,7-bisphosphatase (FBP/SBPase), or a transketolase (TK). In an additional embodiment of this aspect, the CB protein is a SBPase, and the SBPase includes an amino acid sequence with at least 70% sequence identity, at least 71% sequence identity, at least 72% sequence identity, at least 73% sequence identity, at least 74% sequence identity, at least 75% sequence identity, at least 76% sequence identity, at least 77% sequence identity, at least 78% sequence identity, at least 79% sequence identity, at least 80% sequence identity, at least 81% sequence identity, at least 82% sequence identity, at least 83% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 86% sequence identity, at least 87% sequence identity, at least 88% sequence identity, at least 89% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to SEQ ID NO: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 96.
A further aspect of the disclosure includes methods of cultivating the genetically altered plant of any of the preceding embodiments that has a genetically altered plant, including the steps of: planting a genetically altered seedling, a genetically altered plantlet, a genetically altered cutting, a genetically altered tuber, a genetically altered root, or a genetically altered seed in soil to produce the genetically altered plant or grafting the genetically altered seedling, the genetically altered plantlet, or the genetically altered cutting to a root stock or a second plant grown in soil to produce the genetically altered plant; cultivating the plant to produce harvestable seed, harvestable leaves, harvestable roots, harvestable cuttings, harvestable wood, harvestable fruit, harvestable kernels, harvestable tubers, and/or harvestable grain; and harvesting the harvestable seed, harvestable leaves, harvestable roots, harvestable cuttings, harvestable wood, harvestable fruit, harvestable kernels, harvestable tubers, and/or harvestable grain.
One aspect of the present invention provides genetically altered plants, plant parts, or plant cells with modified expression of one or more CB proteins and modified expression of one or more photosynthetic electron transport proteins as compared to the unaltered plants, plant parts, or plant cells. For example, the present disclosure provides genetically altered plants, plant parts, or plant cells with the addition of one or more CB proteins and the addition of one or more photosynthetic electron transport proteins operably linked to a constitutive promoter, an inducible promoter, a tissue or cell type specific promoter, or an inducible, tissue or cell type specific promoter, where the nucleic acid encoding the one or more CB proteins and/or the one or more photosynthetic electron transport proteins has been introduced by genetic alteration of the plant, the promoter has been introduced by genetic alteration of the plant, or both the nucleic acid encoding the one or more CB proteins and/or the one or more photosynthetic electron transport proteins and the promoter have been introduced by genetic alteration of the plant.
Transformation and generation of genetically altered monocotyledonous and dicotyledonous plant cells is well known in the art. See, e.g., Weising, et al., Ann. Rev. Genet. 22:421-477 (1988); U.S. Pat. No. 5,679,558; Agrobacterium Protocols, ed: Gartland, Humana Press Inc. (1995); Wang, et al. Acta Hort. 461:401-408 (1998), and Broothaerts, et al. Nature 433:629-633 (2005). The choice of method varies with the type of plant to be transformed, the particular application and/or the desired result. The appropriate transformation technique is readily chosen by the skilled practitioner.
Any methodology known in the art to delete, insert or otherwise modify the cellular DNA (e.g., genomic DNA and organelle DNA) can be used in practicing the inventions disclosed herein. As an example, the CRISPR/Cas-9 system and related systems (e.g., TALEN, ZFN, ODN, etc.) may be used to insert a heterologous gene to a targeted site in the genomic DNA or substantially edit an endogenous gene to express the heterologous gene or to modify the promoter to increase or otherwise alter expression of an endogenous gene through, for example, removal of repressor binding sites or introduction of enhancer binding sites. For example, a disarmed Ti plasmid, containing a genetic construct for deletion or insertion of a target gene, in Agrobacterium tumefaciens can be used to transform a plant cell, and thereafter, a transformed plant can be regenerated from the transformed plant cell using procedures described in the art, for example, in EP 0116718, EP 0270822, PCT publication WO 84/02913 and published European Patent application (“EP”) 0242246. Ti-plasmid vectors each contain the gene between the border sequences, or at least located to the left of the right border sequence, of the T-DNA of the Ti-plasmid. Of course, other types of vectors can be used to transform the plant cell, using procedures such as direct gene transfer (as described, for example in EP 0233247), pollen mediated transformation (as described, for example in EP 0270356, PCT publication WO 85/01856, and U.S. Pat. No. 4,684,611), plant RNA virus-mediated transformation (as described, for example in EP 0 067 553 and U.S. Pat. No. 4,407,956), liposome-mediated transformation (as described, for example in U.S. Pat. No. 4,536,475), and other methods such as the methods for transforming certain lines of corn (e.g., U.S. Pat. No. 6,140,553; Fromm et al., Bio/Technology (1990) 8, 833-839); Gordon-Kamm et al., The Plant Cell, (1990) 2, 603-618), rice (Shimamoto et al., Nature, (1989) 338, 274-276; Datta et al., Bio/Technology, (1990) 8, 736-740), and the method for transforming monocots generally (PCT publication WO 92/09696). For cotton transformation, the method described in PCT patent publication WO 00/71733 can be used. For soybean transformation, reference is made to methods known in the art, e.g., Hinchee et al. (Bio/Technology, (1988) 6, 915) and Christou et al. (Trends Biotech, (1990) 8, 145) or the method of WO 00/42207.
Genetically altered plants of the present invention can be used in a conventional plant breeding scheme to produce more genetically altered plants with the same characteristics, or to introduce the genetic alteration(s) in other varieties of the same or related plant species. Seeds, which are obtained from the altered plants, preferably contain the genetic alteration(s) as a stable insert in chromosomal DNA or as modifications to an endogenous gene or promoter. Plants including the genetic alteration(s) in accordance with the invention include plants including, or derived from, root stocks of plants including the genetic alteration(s) of the invention, e.g., fruit trees or ornamental plants. Hence, any non-transgenic grafted plant parts inserted on a transformed plant or plant part are included in the invention.
Genetic alterations of the disclosure, including in an expression vector or expression cassette, which result in the expression of an introduced gene or altered expression of an endogenous gene will typically utilize a plant-expressible promoter. A ‘plant-expressible promoter’ as used herein refers to a promoter that ensures expression of the genetic alteration(s) of the invention in a plant cell. Examples of constitutive promoters that are often used in plant cells are the cauliflower mosaic (CaMV) 35S promoter (KAY et al. Science, 236, 4805, 1987), the minimal CaMV 35S promoter (Benfey & Chua, Science, (1990) 250, 959-966), various other derivatives of the CaMV 35S promoter, the figwort mosaic virus (FMV) promoter (Richins, et al., Nucleic Acids Res. (1987) 15:8451-8466) the maize ubiquitin promoter (CHRISTENSEN & QUAIL, Transgenic Res, 5, 213-8, 1996), the trefoil promoter (Ljubql, MAEKAWA et al. Mol Plant Microbe Interact. 21, 375-82, 2008), the vein mosaic cassava virus promoter (International Application WO 97/48819), and the Arabidopsis UBQ10 promoter, Norris et al. Plant Mol. Biol. 21, 895-906, 1993).
Additional examples of promoters directing constitutive expression in plants are known in the art and include: the strong constitutive 35S promoters (the “35S promoters”) of the cauliflower mosaic virus (CaMV), e.g., of isolates CM 1841 (Gardner et al., Nucleic Acids Res, (1981) 9, 2871-2887), CabbB S (Franck et al., Cell (1980) 21, 285-294) and CabbB JI (Hull and Howell, Virology, (1987) 86, 482-493); promoters from the ubiquitin family (e.g., the maize ubiquitin promoter of Christensen et al., Plant Mol Biol, (1992) 18, 675-689), the gos2 promoter (de Pater et al., The Plant J (1992) 2, 834-844), the emu promoter (Last et al., Theor Appl Genet, (1990) 81, 581-588), actin promoters such as the promoter described by An et al. (The Plant J, (1996) 10, 107), the rice actin promoter described by Zhang et al. (The Plant Cell, (1991) 3, 1155-1165); promoters of the figwort mosaic virus (FMV) (Richins, et al., Nucleic Acids Res. (1987) 15:8451-8466), promoters of the Cassava vein mosaic virus (WO 97/48819; Verdaguer et al., Plant Mol Biol, (1998) 37, 1055-1067), the pPLEX series of promoters from Subterranean Clover Stunt Virus (WO 96/06932, particularly the S4 or S7 promoter), an alcohol dehydrogenase promoter, e.g., pAdh1S (GenBank accession numbers X04049, X00581), and the TR1′ promoter and the TR2′ promoter (the “TR1′ promoter” and “TR2′ promoter”, respectively) which drive the expression of the 1′ and 2′ genes, respectively, of the T DNA (Velten et al., EMBO J, (1984) 3, 2723-2730).
Alternatively, a plant-expressible promoter can be a tissue-specific promoter, i.e., a promoter directing a higher level of expression in some cells or tissues of the plant, e.g., in green tissues (such as the promoter of the chlorophyll a/b binding protein (Cab)). The plant Cab promoter (Mitra et al., Planta, (2009) 5: 1015-1022) has been described to be a strong bidirectional promoter for expression in green tissue (e.g., leaves and stems) and is useful in one embodiment of the current invention. These plant-expressible promoters can be combined with enhancer elements, they can be combined with minimal promoter elements, or can include repeated elements to ensure the expression profile desired.
Additional non-limiting examples of tissue-specific promoters include the maize allothioneine promoter (DE FRAMOND et al, FEBS 290, 103-106, 1991; Application EP 452269), the chitinase promoter (SAMAC et al. Plant Physiol 93, 907-914, 1990), the maize ZRP2 promoter (U.S. Pat. No. 5,633,363), the tomato LeExtl promoter (Bucher et al. Plant Physiol. 128, 911-923, 2002), the glutamine synthetase soybean root promoter (HIREL et al. Plant Mol. Biol. 20, 207-218, 1992), the RCC3 promoter (PCT Application WO 2009/016104), the rice antiquitine promoter (PCT Application WO 2007/076115), the LRR receptor kinase promoter (PCT application WO 02/46439), and the Arabidopsis pCO2 promoter (HEIDSTRA et al, Genes Dev. 18, 1964-1969, 2004). Further non-limiting examples of tissue-specific promoters include the RbcS2B promoter, RbcS1B promoter, RbcS3B promoter, LHB1B1 promoter, LHB1B2 promoter, cabl promoter, and other promoters described in Engler et al., ACS Synthetic Biology, DOI: 10.1021/sb4001504, 2014. These plant promoters can be combined with enhancer elements, they can be combined with minimal promoter elements, or can include repeated elements to ensure the expression profile desired.
In some embodiments, further genetic alterations to increase expression in plant cells can be utilized. For example, an intron at the 5′ end or 3′ end of an introduced gene, or in the coding sequence of the introduced gene, e.g., the hsp70 intron. Other such genetic elements can include, but are not limited to, promoter enhancer elements, duplicated or triplicated promoter regions, 5′ leader sequences different from another transgene or different from an endogenous (plant host) gene leader sequence, 3′ trailer sequences different from another transgene used in the same plant or different from an endogenous (plant host) trailer sequence.
An introduced gene of the present disclosure can be inserted in host cell DNA so that the inserted gene part is upstream (i.e., 5′) of suitable 3′ end transcription regulation signals (i.e., transcript formation and polyadenylation signals). This is preferably accomplished by inserting the gene in the plant cell genome (nuclear or chloroplast). Preferred polyadenylation and transcript formation signals include those of the nopaline synthase gene (Depicker et al., J. Molec Appl Gen, (1982) 1, 561-573), the octopine synthase gene (Gielen et al., EMBO J, (1984) 3:835-845), the SCSV or the Malic enzyme terminators (Schunmann et al., Plant Funct Biol, (2003) 30:453-460), and the T DNA gene 7 (Velten and Schell, Nucleic Acids Res, (1985) 13, 6981-6998), which act as 3′ untranslated DNA sequences in transformed plant cells. In some embodiments, one or more of the introduced genes are stably integrated into the nuclear genome. Stable integration is present when the nucleic acid sequence remains integrated into the nuclear genome and continues to be expressed (i.e., detectable mRNA transcript or protein is produced) throughout subsequent plant generations. Stable integration into the nuclear genome can be accomplished by any known method in the art (e.g., microparticle bombardment, Agrobacterium-mediated transformation, CRISPR/Cas9, electroporation of protoplasts, microinjection, etc.).
The term recombinant or modified nucleic acids refers to polynucleotides which are made by the combination of two otherwise separated segments of sequence accomplished by the artificial manipulation of isolated segments of polynucleotides by genetic engineering techniques or by chemical synthesis. In so doing one may join together polynucleotide segments of desired functions to generate a desired combination of functions.
As used herein, the term “overexpression” refers to increased expression (e.g., of mRNA, polypeptides, etc.) relative to expression in a wild type organism (e.g., plant) as a result of genetic modification and can refer to expression of heterologous genes at a sufficient level to achieve the desired result such as increased yield. In some embodiments, the increase in expression is a slight increase of about 10% more than expression in wild type. In some embodiments, the increase in expression is an increase of 50% or more (e.g., 60%, 70%, 80%, 100%, etc.) relative to expression in wild type. In some embodiments, an endogenous gene is upregulated. In some embodiments, an exogenous gene is upregulated by virtue of being expressed. Upregulation of a gene in plants can be achieved through any known method in the art, including but not limited to, the use of constitutive promoters with inducible response elements added, inducible promoters, high expression promoters (e.g., PsaD promoter) with inducible response elements added, enhancers, transcriptional and/or translational regulatory sequences, codon optimization, modified transcription factors, and/or mutant or modified genes that control expression of the gene to be upregulated in response to a stimulus such as cytokinin signaling.
Where a recombinant nucleic acid is intended for expression, cloning, or replication of a particular sequence, DNA constructs prepared for introduction into a host cell will typically include a replication system (e.g., vector) recognized by the host, including the intended DNA fragment encoding a desired polypeptide, and can also include transcription and translational initiation regulatory sequences operably linked to the polypeptide-encoding segment. Additionally, such constructs can include cellular localization signals (e.g., plasma membrane localization signals). In preferred embodiments, such DNA constructs are introduced into a host cell's genomic DNA, chloroplast DNA or mitochondrial DNA.
In some embodiments, a non-integrated expression system can be used to induce expression of one or more introduced genes. Expression systems (expression vectors) can include, for example, an origin of replication or autonomously replicating sequence (ARS) and expression control sequences, a promoter, an enhancer and necessary processing information sites, such as ribosome-binding sites, RNA splice sites, polyadenylation sites, transcriptional terminator sequences, and mRNA stabilizing sequences. Signal peptides can also be included where appropriate from secreted polypeptides of the same or related species, which allow the protein to cross and/or lodge in cell membranes, cell wall, or be secreted from the cell.
Selectable markers useful in practicing the methodologies of the invention disclosed herein can be positive selectable markers. Typically, positive selection refers to the case in which a genetically altered cell can survive in the presence of a toxic substance only if the recombinant polynucleotide of interest is present within the cell. Negative selectable markers and screenable markers are also well known in the art and are contemplated by the present invention. One of skill in the art will recognize that any relevant markers available can be utilized in practicing the inventions disclosed herein.
Screening and molecular analysis of recombinant strains of the present invention can be performed utilizing nucleic acid hybridization techniques. Hybridization procedures are useful for identifying polynucleotides, such as those modified using the techniques described herein, with sufficient homology to the subject regulatory sequences to be useful as taught herein. The particular hybridization techniques are not essential to the subject invention. As improvements are made in hybridization techniques, they can be readily applied by one of skill in the art. Hybridization probes can be labeled with any appropriate label known to those of skill in the art. Hybridization conditions and washing conditions, for example temperature and salt concentration, can be altered to change the stringency of the detection threshold. See, e.g., Sambrook et al. (1989) vide infra or Ausubel et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, NY, N.Y., for further guidance on hybridization conditions.
Additionally, screening and molecular analysis of genetically altered strains, as well as creation of desired isolated nucleic acids can be performed using Polymerase Chain Reaction (PCR). PCR is a repetitive, enzymatic, primed synthesis of a nucleic acid sequence. This procedure is well known and commonly used by those skilled in this art (see Mullis, U.S. Pat. Nos. 4,683,195, 4,683,202, and 4,800,159; Saiki et al. (1985) Science 230:1350-1354). PCR is based on the enzymatic amplification of a DNA fragment of interest that is flanked by two oligonucleotide primers that hybridize to opposite strands of the target sequence. The primers are oriented with the 3′ ends pointing towards each other. Repeated cycles of heat denaturation of the template, annealing of the primers to their complementary sequences, and extension of the annealed primers with a DNA polymerase result in the amplification of the segment defined by the 5′ ends of the PCR primers. Because the extension product of each primer can serve as a template for the other primer, each cycle essentially doubles the amount of DNA template produced in the previous cycle. This results in the exponential accumulation of the specific target fragment, up to several million-fold in a few hours. By using a thermostable DNA polymerase such as the Taq polymerase, which is isolated from the thermophilic bacterium Thermus aquaticus, the amplification process can be completely automated. Other enzymes which can be used are known to those skilled in the art.
Nucleic acids and proteins of the present invention can also encompass homologues of the specifically disclosed sequences. Homology (e.g., sequence identity) can be 50%-100%. In some instances, such homology is greater than 80%, greater than 85%, greater than 90%, or greater than 95%. The degree of homology or identity needed for any intended use of the sequence(s) is readily identified by one of skill in the art. As used herein percent sequence identity of two nucleic acids is determined using an algorithm known in the art, such as that disclosed by Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-2268, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877. Such an algorithm is incorporated into the BLASTN, BLASTP, and BLASTX, programs of Altschul et al. (1990) J. Mol. Biol. 215:402-410. BLAST nucleotide searches are performed with the BLASTN program, score=100, wordlength=12, to obtain nucleotide sequences with the desired percent sequence identity. To obtain gapped alignments for comparison purposes, Gapped BLAST is used as described in Altschul et al. (1997) Nucl. Acids. Res. 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (BLASTN and BLASTX) are used. See www.ncbi.nih.gov. One of skill in the art can readily determine in a sequence of interest where a position corresponding to amino acid or nucleic acid in a reference sequence occurs by aligning the sequence of interest with the reference sequence using the suitable BLAST program with the default settings (e.g., for BLASTP: Gap opening penalty: 11, Gap extension penalty: 1, Expectation value: 10, Word size: 3, Max scores: 25, Max alignments: 15, and Matrix: blosum62; and for BLASTN: Gap opening penalty: 5, Gap extension penalty:2, Nucleic match: 1, Nucleic mismatch −3, Expectation value: 10, Word size: 11, Max scores: 25, and Max alignments: 15).
Preferred host cells are plant cells. Recombinant host cells, in the present context, are those which have been genetically modified to contain an isolated nucleic molecule, contain one or more deleted or otherwise non-functional genes normally present and functional in the host cell, or contain one or more genes to produce at least one recombinant protein. The nucleic acid(s) encoding the protein(s) of the present invention can be introduced by any means known to the art which is appropriate for the particular type of cell, including without limitation, transformation, lipofection, electroporation or any other methodology known by those skilled in the art.
Having generally described this invention, the same will be better understood by reference to certain specific examples, which are included herein to further illustrate the invention and are not intended to limit the scope of the invention as defined by the claims.
The present disclosure is described in further detail in the following examples which are not in any way intended to limit the scope of the disclosure as claimed. The attached figures are meant to be considered as integral parts of the specification and description of the disclosure. The following example is offered to illustrate, but not to limit the claimed disclosure.
The following example describes the generation of constructs and transgenic N. tabacum (tobacco) plants in order to test the combination of manipulation of genes involved in RuBP regeneration with manipulation of genes involved in electron transport. Two different tobacco cultivars with very different growth habits were used: Nicotiana tabacum cv. Petit Havana and Nicotiana tabacum cv. Samsun.
Generation of constructs: Constructs were generated using Golden Gate cloning (Engler, et al., Plos One (2009) 4; Engler, et al., Plos One (2008) 3:e3647) or Gateway cloning technology (Nakagawa, et al., J. Biosci. Bioeng. (2007) 104:34-41). Transgenes were expressed under the control of CaMV35S and FMV constitutive promoters.
For Nicotiana tabacum cv. Petit Havana transgenic lines, the codon optimized cyanobacterial bifunctional fructose-1,6-bisphosphatases/sedoheptulose-1,7-bisphosphatase (FBP/SBPase; slr2094 Synechocystis sp. PCC 7942 (Miyagawa, et al., Nat. Biotechnol. (2001) 19:965-969)) linked to the geraniol synthase transit peptide (Simkin, et al., Phytochemistry (2013) 85:36-43), and the codon optimized P. umbilicalis cytochrome c6 (AFC39870) with the chlorophyll a/b binding protein 6 transit peptide from Arabidopsis thaliana (AT3G54890) were used to generate Golden Gate (Engler, et al., Plos One (2008) 3:e3647) overexpression constructs (EC23083 and EC23028), driven by the FMV (Richins, et al., Nucleic Acids Res. (1987) 15:8451-8466) and CaMV 35S promoters, respectively (
For N. tabacum cv. Samsun transgenic lines, the full-length P. umbilicalis cytochrome c6 gene linked to the transit peptide from the light-harvesting complex I chlorophyll a/b binding protein 6 (AT3G54890), driven by the CaMV 35S promoter, was used to generate over-expression construct B2-C6, in the vector pGWB2 (Nakagawa, et al., J. Biosci. Bioeng. (2007) 104:34-41) (
Production of tobacco transformants: Sixty lines of N. tabacum cv. Petit Havana, and twelve to fourteen lines of N. tabacum cv. Samsun were generated per construct. The recombinant plasmids EC23083 and EC23028 were introduced into WT N. tabacum cv. Petit Havana using Agrobacterium tumefaciens strain LBA4404 via leaf-disc transformation (Horsch, et al., Abstr. Pap. Am. Chem. S. (1985) 190:67), and shoots were regenerated on MS medium containing, hygromycin (20 mg L−1) and cefotaxime (400 mg L−1). Hygromycin resistant primary transformants (T0 generation) with established root systems were transferred to soil and allowed to self-fertilize. T0 and T1 lines expressing the integrated transgenes were screened using semi-quantitative RT-PCR. N. tabacum cv. Petit Havana T2/T3 progeny expressing FBP/SBPase (SB lines: 03, 06, 21, 44) or cytochrome c6 (C6 lines: C15, C41, C47, C50) were selected from primary transformants produced as described above. N. tabacum cv. Petit Havana plants expressing both SB and C6 were generated by crossing SB lines (SB06, SB44, SB21) with C6 lines (C15, C47, C50) to generate four independent SBC6 lines: SBC1 (SB06×C47), SBC2 (SB06×C50), SBC3 (SB44×C47) and SBC6 (SB21×C15). These four independent lines were then allowed to self-pollinate.
The recombinant plasmid B2-C6 was introduced into the SBPase-overexpressing N. tabacum cv. Samsun T4 line described in Lefebvre, et al., Plant Physiol. (2005) 138:451-460, using Agrobacterium tumefaciens strain AGL1 via leaf-disc transformation (Horsch, et al., Abstr. Pap. Am. Chem. S. (1985) 190:67). Primary transformants (T0 generation, 39 plants) were regenerated on MS medium containing kanamycin (100 mg L−1), hygromycin (20 mg L−1) and augmentin (500 mg L−1). Plants expressing the integrated transgenes were screened using semi-quantitative RT-PCR. N. tabacum cv. Samsun lines expressing SBPase+cytochrome c6 (SC6 lines: 1, 2 and 3) were allowed to self-pollinate, and progeny used for subsequent experiments were checked for the presence and expression of the transgene by semi-quantitative RT-PCR.
Control plants used in this study were a combined group of WT and null segregants from the transgenic lines (i.e., azygous lines), which were verified by PCR and semi-quantitative RT-PCR for non-integration of the transgene. A full list of transgenic lines and control lines used in the experiments described in the below examples is provided in Table 1.
N. tabacum
N. tabacum
Selection of tobacco transformants: Semi-quantitative RT-PCR (described in Example 2) was used to detect the presence of the FBP/SBPase transcript in lines SB and SBC6, the presence of the cytochrome c6 transcript in lines C6, SBC6 and SC6, and the presence of the SBPase transcript in lines S and SC6 (
Chlorophyll fluorescence analysis of N. tabacum cv. Petit Havana lines SB, C6 and SBC6 at an irradiance of 600 μmol m−2s−1, or N. tabacum cv. Samsun lines S or SC6 at an irradiance of 650 μmol m−2 s−1 showed that in young plants, the operating efficiency of photosystem two (PSII) photochemistry (Fq′/Fm′) was significantly higher in all transgenic lines compared to either WT or null segregant controls (
cDNA generation: The leaves used for cDNA generation were the same leaves used for photosynthetic measurements (see Example 7). Total RNA was extracted from tobacco leaf disks (sampled from glasshouse-grown plants and quickly frozen in liquid nitrogen) using the NucleoSpin® RNA Plant Kit (Macherey-Nagel, Fisher Scientific, UK). cDNA was synthesized using 1 μg total RNA in 20 μl using the oligo-dT primer according to the protocol in the RevertAid Reverse Transcriptase kit (Fermentas, Life Sciences, UK). cDNA was diluted 1 in 4 to a final concentration of 12.5 ng μL−1.
RT-PCR: For semi-quantitative RT-PCR, 2 μL of RT reaction mixture (100 ng of RNA) in a total volume of 25 μL was used with DreamTaq DNA Polymerase (Thermo Fisher Scientific, UK) according to manufacturer's recommendations. PCR products were fractionated on 1.0% agarose gels. Primers used for semi-quantitative RT-PCR are provided in Table 2, below.
N.
tabacum
N.
tabacum
Wild-type tobacco plants and T1 progeny resulting from self-fertilization of transgenic plants were grown to seed in soil (Levington F2, Fisons, Ipswich, UK). As described in Example 1, for the experiments in N. tabacum cv. Samsun, the null segregants were selected from transformed lines. For the experiments in N. tabacum cv. Petit Havana, the null segregants were selected from the SBC6 lines. Seeds used for experimental study were germinated as described below, and the resulting plants were grown in controlled conditions.
For experimental study, T2-T4 and F1-F3 progeny seeds were germinated on soil in controlled environment chambers at an irradiance of 130 μmol photons m−2 s−1, a temperature of 22° C., in a relative humidity of 60%, and in a 16-h photoperiod (16-h light: 8-h dark). Plants were transferred to individual 8 cm pots and grown for two weeks under the same conditions (irradiance of 130 μmol photons m−2 s−1, temperature of 22° C., relative humidity of 60%, and a 16-h photoperiod). Plants were then transferred to 4 L pots and cultivated in a controlled-environment glasshouse (16-h photoperiod; temperature of between 25° C.-30° C. during the day and 20° C. at night). During periods of low natural light induced by cloud cover, natural light was supplemented with high-pressure sodium light bulbs to provide a minimum irradiance of 380-1000 μmol photons m−2 s−1 (high-light), from the pot level to the top of the plant, respectively. The positions of the plants were changed 3 times each week, and plants were watered regularly with a nutrient medium (Hoagland, et al., The College of Agriculture (1950) 1). Plants were positioned such that at maturity, a near-to-closed canopy was achieved and the temperature range was maintained to be similar to the ambient external environment.
Plants were grown as described in Lopez-Calcagno, et al., Plant Biotechnol. J. (2018). The field site was situated at the University of Illinois Energy Farm (40.11° N, 88.21° W, Urbana, Ill.). Two different experimental designs were used in 2 different years.
The field was prepared in both years as described in Kromdijk, et al., Science (2016) 354:857-861. Light intensity (LI-quantum sensor; LI-COR) and air temperature (Model 109 temperature probe; Campbell Scientific Inc., Logan, Utah) were measured nearby on the same field site, and 15 minute averages (
Leaf discs (0.8 cm in diameter) were taken from the same areas of the leaf used for photosynthetic measurements (see Example 7) and immediately plunged into liquid N2 and stored at −80° C. The leaf discs were ground in dry ice. Protein extractions were performed as described in Lopez-Calcagno, et al., J. Exp. Bot. (2017) 68:2285-2298, or using the Nucleospin RNA/Protein kit (Macherey-Nagel; www.mn-net.com) during RNA preparations. Protein quantification was performed using a protein quantification Kit from Macherey-Nagel. Samples were loaded on an equal protein basis, separated using 12% (w/v) SDS-PAGE, transferred to a nitrocellulose membrane (GE Healthcare Life science, Germany), and probed using antibodies raised against SBPase and FBP/SBPase. Proteins were detected using horseradish peroxidase conjugated to the secondary antibody and ECL chemiluminescence detection reagent (Amersham, Buckinghamshire, UK). SBPase antibodies were previously characterized (Lefebvre, et al., Plant Physiol. (2005) 138:451-460; Dunford, et al., Protein Expr. Purif. (1998) 14:139-145). FBP/SBPase antibodies were raised against a peptide from a conserved region of the protein [C]-DRPRHKELIQEIRNAG-amide (SEQ ID NO: 93), and cytochrome c6 antibodies were raised against peptide [C]-[Nle]-PDKTLKKDVLEANS-amide (SEQ ID NO: 94) (Cambridge Research Biochemicals, Cleveland, UK). In addition to the aforementioned antibodies, samples were probed using antibodies raised against transketolase (Henkes, et al., Plant Cell (2001) 13:535-551; Khozaei, et al., Plant Cell (2015) 27:432-447) and the Glycine decarboxylase H-protein for use as loading controls. Glycine decarboxylase H-protein antibodies were previously characterized in Timm, et al., Febs Lett. (2012) 586:3692-3697.
Whole leaves were harvested from 8 week old plants, washed in cold water and then wiped with a cloth soaked in 80% ethanol to remove the majority of leaf residue. The leaves were then washed twice more in cold water, the midrib was removed, and 50 g of the remaining tissue was placed in a sealed plastic bag and stored overnight in the dark at 4° C. Proteins were extracted as in Hiyama, Methods Mol. Biol. (2004) 274:11-17, with a few modifications. Leaf tissue was homogenized in 250 ml of chilled chloroplast preparation buffer (50 mM sodium phosphate buffer, pH 7, 10 mM NaCl) for 30 seconds. The solution was then filtered through 4 layers of muslin cloth and centrifuged at 10,000×g for 5 minutes. The resulting pellet was then gently resuspended in 50 ml of chilled chloroplast preparation buffer and the chlorophyll concentration was measured and adjusted to approximately 2 mg ml−1. The resulting mixture was then added to two volumes of preheated (45° C.) solubilization medium (50 mM Tris-HCl, pH 8.8, and 3% triton X-100), incubated at 45° C. for 30 minutes, and then chilled in an ice bath for a further 30 minutes before centrifugation at 12000 g for 30 minutes. The supernatant was stored at −80° C. for use in the next stage. To purify cytochrome c6 protein, a Biorad Econo-Pac High-Q 5 ml type wash column was used at a flow rate of 1 ml min−1. First, the column was prepared by washing with 100 ml of starting buffer (10 mM Tris-HCl pH 8.8, 0.2% triton X-100, and 20% sucrose). Then, the protein mixture from the previous step was diluted with an equal volume of chilled starting buffer and passed through the column at a flow rate of 1 ml min−1. Once all the protein was loaded onto the column, it was then washed with 1000 ml of starting buffer supplemented with 10 mM NaCl. The column was then washed with 300 ml of starting buffer supplemented with 50 ml NaCl, and finally the column was eluted with a linear gradient of starting buffer supplemented with NaCl concentrations from 50 mM to 200 mM over a period of 4 hours at a flow rate of 1 ml min−1, with aliquots being collected at multiple times. Samples were mixed with 300 μl of loading buffer (50% glycerol, 25% (3-mercaptoethanol, 25% EDTA) and loaded on an equal protein basis, separated using 18% (w/v) SDS-PAGE, transferred to nitrocellulose membrane, and probed using antibodies raised against cytochrome c6.
FBPase activity was determined by phosphate release as described previously for SBPase with minor modifications (Simkin, et al., J. Exp. Bot. (2015) 66:4075-4090). Leaf discs were obtained from the same leaves used for photosynthetic measurements (see Example 7), and discs were isolated and frozen in liquid nitrogen after photosynthesis measurements were completed. Leaf discs were ground to a fine powder in liquid nitrogen, immersed in extraction buffer (50 mM HEPES, pH8.2; 5 mM MgCl; 1 mM EDTA; 1 mM EGTA; 10% glycerol; 0.1% Triton X-100; 2 mM benzamidine; 2 mM aminocapronic acid; 0.5 mM phenylmethylsulfonylfluoride; 10 mM dithiothreitol), and centrifuged for 1 mM at 14,000×g, 4° C. The resulting supernatant (1 ml) was desalted through a NAP-10 column (Amersham) and stored in liquid nitrogen. The assay was carried out as descried in Simkin, et al., J. Exp. Bot. (2015) 66:4075-4090. In brief, 20 μl of extract were added to 80 μl of assay buffer (50 mM Tris, pH 8.2; 15 mM MgCl2; 1.5 mM EDTA; 10 mM DTT; 7.5 mM fructose-1,6-bisphosphate) and incubated at 25° C. for 30 min. The reaction was stopped by the addition of 50 μl of 1 M perchloric acid. 30 μl of samples or standards (PO3−4 concentrations of 0.125 nmol to 4 nmol) were incubated for 30 min at room temperature following the addition of 300 μl of Biomol Green (Affiniti Research Products, Exeter, UK) and the light absorbance at 620 nm (A620) was measured using a microplate reader (VERSAmax, Molecular Devices, Sunnyvale, Calif.). FBPase activities were normalized to transketolase activity (Zhao, et al., Biomed. Res. Int. (2014) 2014:572915).
Chlorophyll fluorescence imaging was performed on 2-3 week-old tobacco seedlings grown in a controlled environment chamber at 130 μmol mol−2 s−1 and ambient CO2 concentration (400 μmol mol−1). Chlorophyll fluorescence parameters were obtained using a chlorophyll fluorescence (CF) imaging system (Technologica, Colchester, UK (Barbagallo, et al., Plant Physiol. (2003)132:485-493; von Caemmerer, et al., J. Exp. Bot. (2004) 55:1157-1166)). The operating efficiency of photosystem two (PSII) photochemistry, Fq′/Fm′, was calculated from measurements of steady state fluorescence in the light (F′) and maximum fluorescence (Fm′) following a saturating 800 ms pulse of 6300 mmol m−2 s−1 PPFD and using the following equation Fq′/Fm′=(Fm′-F′)/Fm′. Images of Fq′/Fm′ were taken under stable PPFD of 600 μmol m2 s−1 for N. tabacum cv. Petit Havana and under stable PPFD of 650 μmol m2 s−1 for N. tabacum cv. Samsun (Baker, et al., Journal of Experimental Botany (2001) 52:615-621; Oxborough, et al., Philos. Trans. R. Soc. Lond. B. Biol. Sci. (2000) 355:1489-1498; Lawson, et al., J. Exp. Bot. (2008) 59:3609-3619).
Photosynthetic gas-exchange and chlorophyll fluorescence parameters were recorded using a portable infrared gas analyzer (LI-COR 6400; LI-COR, Lincoln, Nebr., USA) with a 6400-40 fluorometer head unit. Unless stated otherwise, all measurements were taken with LI-COR 6400 cuvettes. For plants grown in the glasshouse, conditions were maintained at a CO2 concentration of 400 μmol mol−1, leaf temperature of 25° C., and vapor pressure deficit (VPD) of 1±0.2 kPa. The chamber conditions for plants grown under field conditions had a CO2 concentration of 400 μmol mol−1, the block temperature was set to 2° C. above ambient temperature (ambient air temperature was measured before generation of each gas exchange response curve) and VPD was maintained as close to 1 kPa as possible.
The response of net photosynthesis (A) to intracellular CO2 concentration (Ci) was measured at a saturating light intensity of 2000 μmol mol−2 s−1. Illumination was provided by a red-blue light source attached to the leaf cuvette. Measurements of A were started at ambient CO2 concentration (Ca) of 400 μmol mol−1, before Ca was decreased step-wise to a lowest concentration of 50 μmol mol−1 and then increased step-wise to an upper concentration of 2000 μmol mol−1. To calculate the parameters of maximum saturated CO2 assimilation rate (Amax), maximum carboxylation rate (Vcmax) and maximum electron transport flow (Jmax), the C3 photosynthesis model (Farquhar, et al., Planta (1980) 149:78-90) was fitted to the A/Ci data using a spreadsheet provided by Sharkey, et al., Plant Cell Environ. (2007) 30:1035-1040. Additionally, chlorophyll fluorescence parameters including PSII operating efficiency (Fq′/Fm′) and the coefficient of photochemical quenching (qP), which is mathematically identical to the PSII efficiency factor Fq′/Fv′, were recorded at each point.
Photosynthesis as a function of light (A/Q response curves) was measured under the same cuvette conditions as the A/C curves mentioned above. Leaves were initially stabilized at saturating irradiance of 2200 to μmol m−2 s−1, after which A and gs were measured at the following light levels: 2000 μmol m−2 s−1, 1650 μmol m−2 s−1, 1300 μmol m−2 s−1, 1000 μmol m−2 s1, 750 μmol m−2 s−1, 500 μmol m−2 s−1, 400 μmol m−2 s−1, 300 μmol m−2 200 μmol m−2 s−1, 150 μmol m−2 s−1, 100 μmol m−2 s−1, 50 μmol m−2 s−1 and 0 μmol m−2 Measurements were recorded after A reached a new steady state (1 min to 3 min) and before gs changed to the new light levels. Values of A and gs were used to estimate the intrinsic water-use efficiency (iWUE=A/gs).
All statistical analyses were done using Sys-stat, University of Essex, UK, and R (see the website www.r-project.org). For harvest data, seedling chlorophyll imaging, and enzyme activities, analysis of variance (ANOVA) and Post hoc Tukey tests were done. For gas exchange curves, data were compared by linear mixed model analysis using lmer function and type III ANOVA (Vialet-Chabrand, et al., Plant Physiol. (2017) 173:2163-2179). Significant differences between manipulations were identified using contrasts analysis (lsmeans package).
Transgenic lines selected based on the initial screens described above were grown in the glasshouse, with natural light supplemented to provide illumination of between 400 μmol m−2 s−1 to 1000 μmol m−2 s−1. The rate of net CO2 assimilation (A) and Fq′/Fm′ were determined as a function of internal CO2 concentration (Ci) in mature and developing leaves of N. tabacum cv. Samsun (S and SC6) and in mature leaves of N. tabacum cv. Petit Havana (SB, C6 and SBC6) (
Similar trends were shown for the N. tabacum cv. Petit Havana transgenic plants which displayed higher average values of A, Fq′/Fm′, and Fq′/Fv′ compared to controls (
The developing leaves of both the S and SC6 plants (N. tabacum cv. Samsun) showed significant increases in Jmax and Amax when compared to control plants (Table 3). The mature leaves of the SC6 transgenic plants also displayed a significantly higher VCmax, Jmax, and Amax values relative to the control plants. In contrast, the leaves of the SBC6 plants (N. tabacum cv. Petit Havana) only had significant increases in Amax, although higher average values for Vcmax, and Jmax were evident. These results showed that simultaneous stimulation of electron transport and RuBP regeneration by expression of cytochrome c6 in combination with FBP/SBPase or SBPase has a greater impact on photosynthesis than the single manipulations in all analyzed plants.
N. tabacum
N. tabacum
1Results were determined from the A/Ci curves in FIGS. 7A-7B using the equations published in von Caemmerer, et al., Planta (1981) 153:376-387. Statistical differences are shown in boldface (*p < 0.05), and n = 6-11 plants per manipulation. Mean and SE are shown.
In parallel experiments, N. tabacum cv. Petit Havana plants expressing FBP/SBPase (SB), cytochrome c6 (C6), or FBP/SBPase+cytochrome c6 (SBC6) were grown in controlled conditions for four weeks before harvesting, and N. tabacum cv. Samsun plants expressing SBPase (S), or SBPase+cytochrome c6 (SC6) were grown in controlled conditions for six weeks before harvesting. Height, leaf number, total leaf area and above ground biomass were determined (
To test whether the increases in biomass observed in the transgenic plants under controlled glasshouse conditions could be reproduced in a field environment, a subset of lines was selected for testing in the field. Since larger percent increases in biomass were displayed by the transgenic N. tabacum cv. Petit Havana lines, these plants were selected and tested in three field experiments in two different years (one in 2016, and two in 2017).
In 2016, a small-scale replicated control experiment of the lines expressing single gene constructs for FBP/SBPase (SB) and cytochrome c6 (C6) was carried out to evaluate vegetative growth in the field. Plants were germinated and grown under controlled environment conditions for 26 days before being moved to the field. After 14 days in the field, plants were harvested at an early vegetative stage and plant height, total leaf area, and above ground biomass were measured (
Additionally, in the 2017 field experiments, A as a function of Ci at saturating light (A/Ci) was determined. In the 2017 experiment 1, a significant increase in A was observed in SB and C6 plants without differences in PSII operating efficiency (Fq′/Fm′) (
The above examples describe the generation and analysis of transgenic plants with simultaneous increases in electron transport and improved capacity for RuBP regeneration in two different tobacco cultivars. These examples show that independent stimulation of electron transport (by expression of cytochrome c6) and stimulation of RuBP regeneration (by expression of FBP/SBPase or overexpression of SBPase) increased photosynthesis and biomass in plants grown under controlled conditions. Furthermore, these examples demonstrated that the targeting of these two processes simultaneously (in the SBC6 and SC6 plants) had an even greater effect in stimulating photosynthesis and growth. Additionally, in field studies, the plants with simultaneous stimulation of electron transport and of RuBP regeneration presented increased iWUE and biomass.
Under glasshouse conditions, increases in photosynthetic parameters were observed in all of the analyzed transgenic plants, and these were found to be consistently correlated with increases in biomass. The examples presented here provide the first report of increased photosynthesis and biomass by the simultaneous stimulation of electron transport and RuBP regeneration. Increases in A were observed under glasshouse conditions in the leaves of all analyzed transgenic tobacco plants in both tobacco cultivars tested here (N. tabacum cv. Petit Havana and N. tabacum cv. Samsun). Analysis of the A/Ci response curves showed that the average values for the photosynthetic parameters Vcmax, Jmax, and Amax increased by up to 17%, 14%, and 12%, respectively. These results indicated that not only was the maximal rate of electron transport and RuBP regeneration increased, but the rate of carboxylation by Rubisco was also increased. Although Rubisco activity was not directly targeted, this result is consistent with a study by Wullschleger, et al., J. Exp. Bot. (1993) 44:907-920 of over 100 plant species that showed a linear correlation between Jmax and Vcmax. Furthermore, it has also been shown previously that overexpression of SBPase leads not only to a significant increase in Jmax, but also increases in Vcmax and Rubisco activation state.
Notably, in the greenhouse study, the highest photosynthetic rates were obtained from the leaves of plants in which both electron transport and RuBP regeneration (SBC6 and SC6) were increased, showing that the co-expression of these genes results in an additive effect on improving photosynthesis. In addition to the increases in A, the plants with simultaneous stimulation of electron transport and RuBP regeneration displayed a significant increase in Fq′/Fm′, indicating a higher quantum yield of linear electron flux through PSII compared to the control plants. These results show that reduction of PSI is stimulated by using alternative, more efficient electron donors to PSI (Chida, et al., Plant Cell Physiol. (2007) 48:948-957; Finazzi, et al., Proc. Natl. Acad. Sci. USA. (2005) 102:7031-7036), which is consistent with published data showing that introduction of cytochrome c6 and overexpression of the Rieske FeS protein in Arabidopsis (Simkin, et al., Plant Physiol. (2017) 175:134-145; Chida, et al., Plant Cell Physiol. (2007) 48:948-957) causes increases in the quantum yield of PSII and a more oxidized plastoquinone pool. Furthermore, in the SBC6 and SC6 plants, the increase in Fq′/Fm′ was found to be largely driven by the increase in the PSII efficiency factor (Fq′/Fv′). This suggests that the increase in efficiency in these plants is likely due to stimulation of processes downstream of PSII, such as CO2 assimilation.
To provide further evidence of the applicability of targeting both electron transport and RuBP regeneration to improve crop yields, plants were tested in the field. The field results showed that the expression of FBP/SBPase alone led to an increase in growth and biomass in the 2016 field-grown plants of between 22% to 40% when harvested during early vegetative growth (prior to the onset of flowering). Interestingly, when plants with the same transgenic manipulations were harvested later in development, after the onset of flowering in the 2017 field trials, this advantage was no longer evident and the single FBP/SBPase expressing-lines were indistinguishable from the control plants.
The transgenic plants expressing cytochrome c6 alone also showed enhanced growth and biomass when harvested early in development, but as with the FBP/SBPase plants, this improvement was no longer evident when plants were harvested after flowering. This phenotypic difference in biomass gain between early and late harvest was not observed in a parallel experiment where the overexpression of H-protein was shown to increase biomass under field conditions in plants harvested in early development and after the onset of flowering (López-Calcagno, et al., Plant Biotechnol. J. (2019) 17(1):141-151)). These results suggest that the expression of FBP/SBPase or cytochrome c6 alone may provide an advantage under particular sets of conditions or at specific stages of plant development. This might be exploitable for some crops where an early harvest is desirable (e.g., some types of lettuce, spinach, and tender greens) (Ichikawa, et al., GM Crops (2010) 1:322-326). In contrast with the results with the single manipulations described above, plants simultaneously expressing both cytochrome c6 and FBP/SBPase displayed a consistent increase in biomass after flowering under field conditions.
In the transgenic lines grown in the field, the correlations between increases in photosynthesis and biomass were less consistent than those observed under glasshouse conditions. The transgenic lines with individual manipulations, namely FBP/SBPase (SB lines) and cytochrome c6 (C6 lines) had significant increases in photosynthetic capacity in the 2017 experiment 1, without an increase in biomass. In contrast, the C6 lines in 2017 experiment 2 had increased biomass, but no significant differences in photosynthetic capacity. The transgenic lines with double gene manipulations, namely FBP/SBPase+cytochrome c6 (SBC6) also had increased biomass without significant differences in photosynthetic capacity in 2017 experiment 2. Across all experiments, the average A values of the transgenic plants were consistently higher than those of the controls. Even if the differences were not consistently statistically different across all experiments, it is known that even small increases in assimilation throughout the lifetime of a plant will have a cumulative effect, which could translate into a significant biomass accumulation (Simkin, et al., J. Exp. Bot. (2015) 66:4075-4090).
At light intensities above 1000 μmol m−2 s−1, it was observed that plants with simultaneous expression of FBP/SBPase+cytochrome c6 (SBC6) had lower stomatal conductance (gs) and lower Ci concentration when compared to control plants (
The results in these examples provide support for the proposal that the increased photosynthetic capacity in SBC6 plants compensates for the reduction Ci. The higher iWUE and the fact that a higher productivity compared to controls has been reported in field studies with CO2 enrichment (Rosenthal, et al., BMC Plant Biol. (2011) 11:123; Ichikawa, et al., GM Crops (2010) 1:322-326) for transgenic lines with increased RuBP regeneration highlights the potential of manipulating electron transport and RuBP regeneration for the development of new plant varieties able to sustain photosynthesis and yields under climate change scenarios.
The results in these examples provide a clear demonstration that combining manipulations leading to simultaneous stimulation of electron transport and RuBP regeneration under the conditions tested leads to significant increases in biomass over the single manipulations and emphasizes the potential of this strategy for the development of high yielding crops.
This application claims the benefit of U.S. Provisional Application No. 62/821,786, filed Mar. 21, 2019, which is hereby incorporated by reference in its entirety.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/EP2020/057475 | 3/18/2020 | WO | 00 |
Number | Date | Country | |
---|---|---|---|
62821786 | Mar 2019 | US |